Drug-eluting self-retaining sutures and methods relating thereto

US11007296B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11007296-B2
Application numberUS-201113883066-A
CountryUS
Kind codeB2
Filing dateNov 3, 2011
Priority dateNov 3, 2010
Publication dateMay 18, 2021
Grant dateMay 18, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A drug-eluting self-retaining suture comprises a filament, a plurality of retainers, and a drug impregnated in or coated on the filament. The shape and distribution of retainers modifies the in vivo release kinetics of the drug. The drug release kinetics may be modified uniformly or region by region. The self-retaining suture may for example be used for reattaching severed nerves and release nerve growth factor or other regeneration accelerating agents into the region of the nerve injury.

First claim

Opening claim text (preview).

What is claimed is: 1. A suture comprising: (a) a filament, wherein the filament comprises: i) a core, ii) a sheath, iii) a first end portion, iv) a second end portion, and v) a middle portion between the first end portion and the second end portion; wherein the sheath comprises a plurality of triangular-shaped sheath elements and wherein each of the plurality of triangular-shaped sheath elements: 1) is angularly spaced apart from adjacent triangular-shaped sheath elements of the plurality of triangular-shaped sheath elements about a circumference of the core, and 2) has a base and a tip that is narrower than the base, wherein: A. the base is connected to the core, and B. the tip extends radially outward from the core; (b) triclosan associated with the sheath of the filament; and (c) a plurality of tissue retainers formed in the filament; wherein: i) at least one of the first end portion, the second end portion and the middle portion has a higher concentration of the triclosan than another of the first end portion, the second end portion, and the middle portion; ii) kinetics of release of the triclosan from the suture is determined by a distribution of the triclosan on the retainers, a density of the retainers, a size of the retainers, a surface area of the retainers and a shape of the retainers; and iii) the suture comprises at least one non-degradable material selected from the group of polyamide, polyester, polytetrafluoroethylenes, polyether-ester, 4-hydroxybutyrate, polyhydroxylalkanoate, polyurethane, metals, metal alloys, polypropylene, polyethylene, silk, cotton and combinations thereof. 2. The suture of claim 1 , wherein the suture further comprises at least one polymer selected from the group of poly(L-lactic acid), poly(p-dioxanone), poly(DL-lactic acid), polycaprolactone, poly(glycolic acid), polyanhydride, polyglycolic acid homopolymer, copolymers of glycolide and ϵ-caprolactone, copolymers of glycolide and lactide, copolymers of trimethylene carbonate and glycolide with diethylene glycol, polyhydroxylalkanoates, terpolymer composed of glycolide, trimethylene carbonate and dioxanone, trimethylene carbonate (26%) and dioxanone (14%), copolymers of glycolide, caprolactone, trimethylene carbonate and lactide. 3. The suture of claim 2 , wherein the suture further comprises at least one naturally occurring polymer selected from the group of reconstituted collagen, fibrin, natural silks, cellulose, starch, chitin, polypeptides modified polysaccharides, modified proteins and combinations thereof. 4. A suture comprising: (a) a filament, wherein the filament comprises: i) a core, ii) a sheath, iii) a first end portion, iv) a second end portion, and v) a middle portion between the first end portion and the second end portion; wherein the sheath comprises a plurality of triangular-shaped sheath elements and wherein each of the plurality of triangular-shaped sheath elements: 1) is angularly spaced apart from adjacent triangular-shaped sheath elements of the plurality of triangular-shaped sheath elements about a circumference of the core, and 2) has a base and a tip that is narrower than the base, wherein: A. the base is connected to the core, and B. the tip extends radially outward from the core; (b) Nerve Growth Factor (NGF) integrated into the filament; and (c) a plurality of tissue retainers formed in the filament; wherein: i) at least one of the first end portion, the second end portion and the middle portion has a higher concentration of the NGF than another of the first end portion, the second end portion, and the middle portion; and ii) the kinetics of release of the NGF from the suture is determined by at least one of a distribution of the retainers, a density of the retainers, a size of the retainers, a surface area of the retainers or a shape of the retainers; iii) wherein first order burst in-vitro release kinetics of the NGF is such that at least about 80% of the NGF is released from the suture on day 5 after implantation of the suture; and iv) the suture comprises at least one non-degradable material selected from the group of polyamide, polyester, polytetrafluoroethylenes, polyether-ester, 4-hydroxybutyrate, polyhydroxylalkanoate, polyurethane, metals, metal alloys, polypropylene, polyethylene, silk, cotton and combinations thereof. 5. The suture of claim 4 , wherein the suture further comprises at least one polymer selected from the group of poly(L-lactic acid), poly(p-dioxanone), poly(DL-lactic acid), polycaprolactone, poly(glycolic acid), polyanhydride, polyglycolic acid homopolymer, copolymers of glycolide and ϵ-caprolactone, copolymers of glycolide and lactide, copolymers of trimethylene carbonate and glycolide with diethylene glycol, polyhydroxylalkanoates, terpolymer composed of glycolide, trimethylene carbonate and dioxanone, trimethylene carbonate (26%) and dioxanone (14%), copolymers of glycolide, caprolactone, trimethylene carbonate and lactide. 6. The suture of claim 5 , wherein the suture further comprises at least one naturally occurring polymer selected from the group of reconstituted collagen, fibrin, natural silks, cellulose, starch, chitin, polypeptides modified polysaccharides, modified proteins and combinations thereof.

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11007296B2 cover?
A drug-eluting self-retaining suture comprises a filament, a plurality of retainers, and a drug impregnated in or coated on the filament. The shape and distribution of retainers modifies the in vivo release kinetics of the drug. The drug release kinetics may be modified uniformly or region by region. The self-retaining suture may for example be used for reattaching severed nerves and release ne…
Who is the assignee on this patent?
Gross Jeffrey M, Drubetsky Lev, Naimagon Alexander, and 8 more
What technology area does this patent fall under?
Primary CPC classification A61L17/005. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue May 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).